Clarus Therapeutics Holdings Revenue Growth Rates (CRXT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Clarus Therapeutics Holdings Inc.  (NASDAQ: CRXT)
 

CRXT's Revenue Growth by Quarter and Year

Clarus Therapeutics Holdings's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CRXT Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June 4.05
1st Quarter March 4.01
FY 8.06





CRXT Revenue second quarter 2022 Y/Y Growth Comment
Clarus Therapeutics Holdings Inc. reported Revenue rise of 45.68% year on year in the second quarter 2022, to $ 4.05 millions, this is lower than Clarus Therapeutics Holdings Inc.'s recent average Revenue rise of 47.32%.

Looking into second quarter 2022 results within Biotechnology & Pharmaceuticals industry 46 other companies have achieved higher Revenue growth. While Clarus Therapeutics Holdings Inc.' s Revenue jump of 45.68% ranks overall at the positon no. 3023 in the second quarter 2022.


CRXT Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 9.88 % - -
3rd Quarter September - 93.24 % - -
2nd Quarter June 45.68 % - - -
1st Quarter March 72.1 % - - -
FY   - 119.15 % - -

Financial Statements
Clarus Therapeutics Holdings's second quarter 2022 Revenue $ 4.05 millions CRXT's Income Statement
Clarus Therapeutics Holdings's second quarter 2021 Revenue $ 2.78 millions Quarterly CRXT's Income Statement


CRXT Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 6.29 % 86.94 % -
3rd Quarter September - 54.32 % - -
2nd Quarter June 1 % 19.31 % - -
1st Quarter March -12.06 % -43.86 % - -
FY (Year on Year)   - 119.15 % - -


Back to CRXT Growth rate Comparisons >> Back to CRXT Growth rate Comparisons >>


Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #47
Healthcare Sector #410
Overall #3023

Revenue Y/Y Growth Statistics
High Average Low
47.32 % 47.32 % 47.32 %
(Jun 30 2022)  
Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #47
Healthcare Sector #410
Overall #3023
Revenue Y/Y Growth Statistics
High Average Low
47.32 % 47.32 % 47.32 %
(Jun 30 2022)  

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Clarus Therapeutics Holdings's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0.97 % 0.97 % 0.97 %
(Jun 30 2022)  


CRXT's II. Quarter Q/Q Revenue Comment
Clarus Therapeutics Holdings Inc. achieved in the II. Quarter 2022 above company average sequential Revenue growth of 1%, to $ 4.05 millions, from $4.01 millions in the first quarter.

Within Biotechnology & Pharmaceuticals industry 77 other companies have achieved higher Revenue quarter on quarter growth. While Clarus Therapeutics Holdings's Revenue growth quarter on quarter, overall rank is 2509.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #78
Healthcare Sector #397
Overall #2509
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #78
Healthcare Sector #397
Overall #2509
Revenue Q/Q Growth Statistics
High Average Low
0.97 % 0.97 % 0.97 %
(Jun 30 2022)  


CRXT's II. Quarter Q/Q Revenue Comment
Clarus Therapeutics Holdings Inc. achieved in the II. Quarter 2022 above company average sequential Revenue growth of 1%, to $ 4.05 millions, from $4.01 millions in the first quarter.

Within Biotechnology & Pharmaceuticals industry 77 other companies have achieved higher Revenue quarter on quarter growth. While Clarus Therapeutics Holdings's Revenue growth quarter on quarter, overall rank is 2509.


Clarus Therapeutics Holdings's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)
Cumulative Revenue 12 Months Ending $ 16.91 $ 15.64 $ 13.96 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 47.32 % - - - -
Year on Year Revenue Growth Overall Ranking # 842 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 8.13 % 12.04 % 3.08 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 3023 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With 47.32% annual Revenue growth, Clarus Therapeutics Holdings Inc. would report a record annual Revenue growth if the fiscal year would end on Jun 30 2022.

In the Healthcare sector 144 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 842.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 47
Healthcare Sector # 145
Overall # 842

Revenue TTM Y/Y Growth Statistics
High Average Low
47.32 %
 47.32 %
47.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 47
Sector # 410
S&P 500 # 3023
Cumulative Revenue growth Comment
With 47.32% annual Revenue growth, Clarus Therapeutics Holdings Inc. would report a record annual Revenue growth if the fiscal year would end on Jun 30 2022.

In the Healthcare sector 144 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 842.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 47
Healthcare Sector # 145
Overall # 842

Revenue TTM Y/Y Growth Statistics
High Average Low
47.32 %
47.32 %
47.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 47
Sector # 410
S&P 500 # 3023




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CRXT's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2022
Agile Therapeutics Inc79.41%$ 79.409 millions
Precision Optics Corporation Inc 79.31%$ 79.313 millions
Docgo Inc 76.12%$ 76.116 millions
Karyopharm Therapeutics Inc 75.56%$ 75.563 millions
Adaptimmune Therapeutics Plc75.39%$ 75.394 millions
Icu Medical Inc74.40%$ 74.400 millions
Mymetics Corporation73.70%$ 73.702 millions
Bionano Genomics Inc 72.98%$ 72.977 millions
Inspire Medical Systems inc 72.56%$ 72.560 millions
Solid Biosciences Inc 71.65%$ 71.647 millions
Senti Biosciences Holdings Inc 71.25%$ 71.248 millions
Petros Pharmaceuticals inc 70.35%$ 70.349 millions
Electrocore Inc 69.91%$ 69.914 millions
Collegium Pharmaceutical Inc 68.39%$ 68.389 millions
Biofrontera Inc 67.86%$ 67.857 millions
Scienture Holdings Inc 67.04%$ 67.044 millions
Abcellera Biologics Inc 66.11%$ 66.107 millions
Therapeutic Solutions International Inc 65.28%$ 65.283 millions
Neptune Wellness Solutions Inc 61.45%$ 61.455 millions
Armata Pharmaceuticals Inc 61.22%$ 61.216 millions
Innovative Eyewear Inc 61.21%$ 61.213 millions
Cvrx inc 61.10%$ 61.095 millions
Volitionrx Limited60.41%$ 60.407 millions
Twist Bioscience Corporation60.24%$ 60.240 millions
G1 Therapeutics Inc 60.10%$ 60.100 millions
Mirum Pharmaceuticals Inc 58.95%$ 58.945 millions
Marpai Inc57.34%$ 57.341 millions
Skinhealth Systems Inc 55.67%$ 55.675 millions
Sanara Medtech Inc 54.06%$ 54.064 millions
Eagle Pharmaceuticals inc 54.05%$ 54.052 millions


About Clarus Therapeutics Holdings Revenue Growth Rates (CRXT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Clarus Therapeutics Holdings Inc (CIK 1817944).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-22-224410
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Clarus Therapeutics Holdings Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.